This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Bionano Genomics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Bionano Genomics's earnings have been declining at an average annual rate of -43.5%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 26% per year.
Belangrijke informatie
-43.5%
Groei van de winst
59.7%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.8% |
| Inkomstengroei | 26.0% |
| Rendement op eigen vermogen | -68.2% |
| Nettomarge | -465.0% |
| Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Bionano Genomics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 23 | 32 | -147 | 97 | 55 |
| 31 Mar 23 | 30 | -140 | 92 | 52 |
| 31 Dec 22 | 28 | -133 | 86 | 49 |
| 30 Sep 22 | 26 | -117 | 81 | 44 |
| 30 Jun 22 | 23 | -106 | 76 | 38 |
| 31 Mar 22 | 21 | -92 | 68 | 30 |
| 31 Dec 21 | 18 | -72 | 57 | 22 |
| 30 Sep 21 | 16 | -61 | 47 | 16 |
| 30 Jun 21 | 13 | -51 | 40 | 12 |
| 31 Mar 21 | 11 | -41 | 32 | 10 |
| 31 Dec 20 | 9 | -41 | 30 | 10 |
| 30 Sep 20 | 7 | -37 | 28 | 10 |
| 30 Jun 20 | 8 | -33 | 23 | 10 |
| 31 Mar 20 | 9 | -32 | 23 | 10 |
| 31 Dec 19 | 10 | -30 | 20 | 9 |
| 30 Sep 19 | 11 | -28 | 18 | 10 |
| 30 Jun 19 | 11 | -27 | 17 | 10 |
| 31 Mar 19 | 12 | -23 | 16 | 9 |
| 31 Dec 18 | 12 | -18 | 14 | 9 |
| 30 Sep 18 | 11 | -18 | 13 | 9 |
| 30 Jun 18 | 11 | -18 | 13 | 10 |
| 31 Mar 18 | 10 | -22 | 14 | 11 |
| 31 Dec 17 | 10 | -23 | 14 | 12 |
| 31 Dec 16 | 7 | -19 | 13 | 11 |
Kwaliteitswinsten: 2Y30 is currently unprofitable.
Groeiende winstmarge: 2Y30 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2Y30 is unprofitable, and losses have increased over the past 5 years at a rate of 43.5% per year.
Versnelling van de groei: Unable to compare 2Y30's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 2Y30 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.2%).
Rendement op eigen vermogen
Hoge ROE: 2Y30 has a negative Return on Equity (-68.23%), as it is currently unprofitable.